CALM2-CAH: Long-term Extension Study of Atumelnant in Congenital Adrenal Hyperplasia

Phase 2, open-label, single-arm trial of atumelnant in congenital adrenal hyperplasia (CAH), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse… at 108 weeks, Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisis at 108 weeks and 2 more. Started Feb 2025; status: recruiting.